Analyst Ratings Network logo

NASDAQ:ACCD - Accolade Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.00
  • Forecasted Upside: 1.24 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$52.35 As of 01/15/2021 01:00 AM ET
▲ +4.59 (9.61%)
1 month | 3 months | 12 months
Get New Accolade Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACCD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$53.00
▲ +1.24% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $53.00, with a high forecast of $60.00 and a low forecast of $39.00. The average price target represents a 1.24% upside from the last price of $52.35.
Buy
The current consensus among 11 polled investment analysts is to buy stock in Accolade.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$55.00 ➝ $60.00High
i
1/15/2021Robert W. BairdBoost Price TargetOutperform$50.00 ➝ $55.00High
i
Rating by Matthew Gillmor at Robert W. Baird
1/15/2021SVB LeerinkBoost Price TargetMarket Perform$53.00 ➝ $56.00High
i
1/15/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00 ➝ $60.00High
i
1/8/2021Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $45.00High
i
1/8/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$45.00 ➝ $50.00High
i
Rating by Matthew Gillmor at Robert W. Baird
1/8/2021SVB LeerinkBoost Price TargetMarket Perform$44.00 ➝ $53.00High
i
1/8/2021Piper SandlerBoost Price TargetOverweight$55.00 ➝ $57.00High
i
1/6/2021BTIG ResearchInitiated CoverageBuy$55.00N/A
i
12/8/2020Canaccord GenuityInitiated CoverageBuy$59.00High
i
11/16/2020Stifel NicolausInitiated CoverageBuy$48.00High
i
10/16/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $48.00Medium
i
10/15/2020Bank of AmericaBoost Price TargetBuy$45.00 ➝ $51.00High
i
10/15/2020DA DavidsonBoost Price TargetPositive ➝ Buy$45.00 ➝ $50.00High
i
Rating by H. Baade at DA Davidson
10/15/2020SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $44.00Low
i
10/15/2020Robert W. BairdBoost Price TargetOutperform$40.00 ➝ $45.00Low
i
Rating by Matthew Gillmor at Robert W. Baird
10/15/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $55.00Low
i
10/8/2020Bank of AmericaBoost Price TargetBuy$42.50 ➝ $45.00Medium
i
9/22/2020DA DavidsonInitiated CoverageBuy$45.00High
i
Rating by H. Baade at DA Davidson
8/14/2020Credit Suisse GroupBoost Price TargetNeutral$38.00 ➝ $40.00High
i
8/14/2020SVB LeerinkBoost Price TargetMarket Perform$34.00 ➝ $40.00High
i
7/27/2020Robert W. BairdInitiated CoverageOutperform$40.00High
i
7/27/2020SVB LeerinkInitiated CoverageOutperform$34.00High
i
7/27/2020Bank of AmericaInitiated CoverageBuy$37.00High
i
7/27/2020Piper SandlerInitiated CoverageOverweight$45.00High
i
7/27/2020The Goldman Sachs GroupInitiated CoverageBuy$39.00High
i
7/27/2020Credit Suisse GroupInitiated CoverageNeutral$38.00High
i
7/27/2020Morgan StanleyInitiated CoverageOverweight$37.00High
i
(Data available from 1/19/2016 forward)
Accolade logo
Accolade, Inc. develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $52.35
$51.06
$54.60

50 Day Range

MA: $50.27
$41.45
$59.72

52 Week Range

Now: $52.35
$28.68
$65.25

Volume

2,546,626 shs

Average Volume

758,442 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Accolade?

The following Wall Street sell-side analysts have issued research reports on Accolade in the last year: Bank of America Co., BTIG Research, Canaccord Genuity, Credit Suisse Group AG, DA Davidson, Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.

What is the current price target for Accolade?

11 Wall Street analysts have set twelve-month price targets for Accolade in the last year. Their average twelve-month price target is $53.00, suggesting a possible upside of 1.2%. BTIG Research has the highest price target set, predicting ACCD will reach $60.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $39.00 for Accolade in the next year.

What is the current consensus analyst rating for Accolade?

Accolade currently has 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACCD will outperform the market and that investors should add to their positions of Accolade.

What other companies compete with Accolade?

Other companies that are similar to Accolade include The Western Union, WEX, Nielsen, Fiverr International, Grubhub, Ritchie Bros. Auctioneers, American Well, CDK Global, Concentrix, Shift4 Payments, HealthEquity, TriNet Group, MultiPlan, Maximus and Envestnet.

How do I contact Accolade's investor relations team?

Accolade's physical mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 347-574-3820 and its investor relations email address is ir@accolade.com. The official website for Accolade is accolade.com.